Literature DB >> 6258288

Pancreatic glucagonoma with and without syndrome. Immunocytochemical study of 5 tumour cases and review of the literature.

E Ruttman, G Klöppel, G Bommer, M Kiehn, P U Heitz.   

Abstract

In five patients single or multiple glucagonomas were characterized by immunocytochemistry. Two large single glucagonomas were associated with the glucagonoma syndrome, which completely dissappeared after removal of the tumours. The morphologic findings in these patients are compared with 48 others collected from literature. In the other three patients, the glucagonomas were not associated with a clinical syndrome and were detected by chance (one accompanying an insulinoma; the other in pancreases of patients suffering from multiple endocrine neoplasia I; MEN I). These tumours appeared by their histological, immunocytochemical and ultrastructural features better organized than the glucagonomas with syndrome. Glucagonomas not producing a syndrome can be classified into (a) solitary, often malignant endocrine pancreatic tumours, (b) glucagonomas associated with insulinomas and other tumours, (c) multiple glucagonomas in MEN I and (d) single microglucagonomas in elderly patients. It is emphasized that only immunohistology allows clear identification of these tumours as glucagonomas.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6258288     DOI: 10.1007/bf00430676

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histol        ISSN: 0340-1227


  63 in total

1.  Observations on the aetiology and treatment of anaemia in kwashiorkor.

Authors:  E B Adams; J N Scragg; B T Naidoo; S K Liljestrand; V I Cockram
Journal:  Br Med J       Date:  1967-08-19

2.  The glucagonoma syndrome.

Authors:  J L Shupack; P H Berczeller; D M Stevens
Journal:  J Dermatol Surg Oncol       Date:  1978-03

3.  The glucagonoma syndrome and its management.

Authors:  A Kessinger; H M Lemon; J F Foley
Journal:  J Surg Oncol       Date:  1977       Impact factor: 3.454

4.  Metabolic studies and glucagon gel filtration pattern before and after surgery in a case of glucagonoma syndrome.

Authors:  H von Schenck; J I Thorell; J Berg; G Bojs; J F Dymling; B Hallengren; O Ljungberg; S Tibblin
Journal:  Acta Med Scand       Date:  1979

5.  [Endocrine pancreatic neoplasms. Morphology and syndromes].

Authors:  G Klöppel; G Seifert; P U Heitz
Journal:  Dtsch Med Wochenschr       Date:  1979-11-02       Impact factor: 0.628

6.  A silver nitrate stain for alpha-2 cells in human pancreatic islets.

Authors:  L Grimelius
Journal:  Acta Soc Med Ups       Date:  1968

7.  Skin rash in patient receiving glucagon.

Authors:  S G Barber; J D Hamer
Journal:  Lancet       Date:  1976-11-20       Impact factor: 79.321

8.  Pathology of the endocrine pancreas.

Authors:  P U Heitz; M Kasper; J M Polak; G Klöppel
Journal:  J Histochem Cytochem       Date:  1979-10       Impact factor: 2.479

9.  A study of glucagonomas by light and electron microscopy and immunofluorescence.

Authors:  C Bordi; M Ravazzola; D Baetens; P Gorden; R H Unger; L Orci
Journal:  Diabetes       Date:  1979-10       Impact factor: 9.461

10.  Functional studies in patients with the glucagonoma syndrome.

Authors:  J J Holst; S Helland; S Ingemannson; N B Pedersen; H von Schenck
Journal:  Diabetologia       Date:  1979-09       Impact factor: 10.122

View more
  13 in total

1.  Endoscopic findings of a pancreatic glucagonoma.

Authors:  A G Guirado; P Sanchez-Fayos; O Bosch; M J Relloso; C Rivas; J C Porres
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

2.  Glucagon expression in cystic pancreatic neuroendocrine neoplasms: an immunohistochemical analysis.

Authors:  Björn Konukiewitz; Tetsuji Enosawa; Günter Klöppel
Journal:  Virchows Arch       Date:  2010-10-05       Impact factor: 4.064

Review 3.  Revised classification of neuroendocrine tumours of the lung, pancreas and gut.

Authors:  C Capella; P U Heitz; H Höfler; E Solcia; G Klöppel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

4.  Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2.

Authors:  Gratiana Hermann; Björn Konukiewitz; Anja Schmitt; Aurel Perren; Günter Klöppel
Journal:  Virchows Arch       Date:  2011-07-08       Impact factor: 4.064

5.  Gastroenteropancreatic endocrine tumors.

Authors:  C Weil
Journal:  Klin Wochenschr       Date:  1985-05-15

6.  Prognostic criteria in nonfunctioning pancreatic endocrine tumours.

Authors:  S La Rosa; F Sessa; C Capella; C Riva; B E Leone; C Klersy; G Rindi; E Solcia
Journal:  Virchows Arch       Date:  1996-12       Impact factor: 4.064

7.  Glucagonomas of transgenic mice express a wide range of general neuroendocrine markers and bioactive peptides.

Authors:  G Rindi; S Efrat; M A Ghatei; S R Bloom; E Solcia; J M Polak
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

Review 8.  [Tumors of the endocrine pancreas].

Authors:  G Klöppel
Journal:  Pathologe       Date:  2003-05-29       Impact factor: 1.011

9.  Conditional deletion of p53 and Rb in the renin-expressing compartment of the pancreas leads to a highly penetrant metastatic pancreatic neuroendocrine carcinoma.

Authors:  S T Glenn; C A Jones; S Sexton; C M LeVea; S M Caraker; G Hajduczok; K W Gross
Journal:  Oncogene       Date:  2013-12-02       Impact factor: 9.867

10.  An immunohistochemical study of glucagonoma conducted on the metastatic lymph nodes from a patient with recurrent metastatic glucagonoma: report of a case.

Authors:  N Kawakita; Y Nagahata; K Yoshizumi; T Wada; M Yamamoto; Y Saitoh; T Urakawa
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.